JUNSHI BIO - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

or completeness of this announcement, and expressly expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by relying on such content.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

Shanghai Junshi Biomedical Technology Co., Ltd. (a joint stock limited company incorporated in the People's Republic of China) (Stock code: 1877)

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

This is to set forth the "Shanghai Announcement of the Resolutions of the 2025 Annual Shareholders Meeting of Junshi Biomedical Technology Co., Ltd.", "Beijing Jiayuan Law

The law firm’s legal opinion on the 2025 annual shareholders’ meeting of Shanghai Junshi Biomedical Technology Co., Ltd. Book" for reference only.

By order of the board of directors Shanghai Junshi Biomedical Technology Co., Ltd.

Mr. Xiong Jun Chairman

China, Shanghai, June 26, 2026

As of the date of this announcement, the Company’s Board of Directors includes Executive Directors Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin; non-executive directors Dr. Yao Sheng and Tang Yixian students; and independent non-executive directors Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Chen Liang

Sir.

*For identification purposes only

Securities code: 688180 Securities abbreviation: Junshi Biotechnology Announcement number: Lin 2026-037

Shanghai Junshi Biomedical Technology Co., Ltd.

Annual Shareholders Meeting Resolution Announcement 2025

The company's board of directors and all directors guarantee that the announcement does not contain any false records or misleading statements.

or major omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important content reminder:

 Whether any motions were rejected at this meeting: None

1. Meeting convening and attendance

(1) Time of the shareholders’ meeting: June 26, 2026

(2) The location of the shareholders' meeting: Floor 15, Building 7, No. 6, Lane 100, Pingjiaqiao Road, Pudong New District, Shanghai

(3) Common shareholders, special voting rights shareholders, preference shareholders whose voting rights have been restored and those attending the meeting The number of voting rights it holds:

1. Number of shareholders and proxies attending the meeting 216

Among them: Number of A-share shareholders 215 Number of shareholders of overseas listed foreign shares (H shares) 1

2. Number of voting rights held by shareholders attending the meeting 303,991,516

Among them: the number of voting rights held by A-share shareholders 294,845,577

Number of voting rights held by shareholders of overseas listed foreign shares (H shares) 9,145,939

3. The number of voting rights held by shareholders attending the meeting accounts for the number of voting rights of the company. 29.6324 Proportion (%) Among them: the number of voting rights held by A-share shareholders accounts for 28.7409 of the company’s voting rights

Proportion (%)

Number of voting rights held by shareholders of overseas listed foreign shares (H shares) 0.8915 Proportion of the number of voting rights in the company (%)

(4) Whether the voting method complies with the provisions of the Company Law and the company's articles of association, and the status of the shareholders' meeting, etc.

Shareholders of Shanghai Junshi Biomedical Technology Co., Ltd. (hereinafter referred to as the "Company") in 2025

All proposals will be considered through a combination of on-site voting and online voting. This shareholders’ meeting is convened by the board of directors.

Chairman Xiong Jun presided over this meeting. The convening, holding and voting methods of the meeting comply with the Company Law

and other laws, regulations, normative documents and company articles of association.

(5) Attendance of company directors and board secretaries

1. The company has 14 current directors and 14 people are present;

2. Mr. Wang Zhengyu, Secretary of the Company’s Board of Directors, attended this shareholders’ meeting; some senior managers attended this meeting as non-voting delegates.

Donghui.

2. Proposal review status

(1) Non-cumulative voting proposals

1. Proposal Name: Proposal on the "2025 Board of Directors Work Report" Review result: Passed

Voting status:

Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 303,384,219 99.8002 560,750 0.1845 46,547 0.0153

Among them: A shares 294,286,680 99.8104 512,350 0.1737 46,547 0.0159 Overseas listed foreign capital 9,097,539 99.4708 48,400 0.5292 0 0.0000 shares (H shares)

2. Proposal Name: Proposal on the "2025 Annual Report" and Summary

Review result: Passed

Voting status:

Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 303,377,528 99.8013 552,341 0.1817 51,647 0.0170

Among them: A shares 294,289,989 99.8115 503,941 0.1709 51,647 0.0176 Overseas listed foreign capital 9,087,539 99.4702 48,400 0.5298 0 0.0000 shares (H shares)

3. Proposal Name: Proposal on the "2025 Profit Distribution Plan"

Review result: Passed

Voting status:

Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 303,356,594 99.7944 596,157 0.1961 28,765 0.0095 Among them: A shares 294,220,655 99.7880 596,157 0.2021 28,765 0.0099

Outside of overseas listing 9,135,939 100.0000 0 0.0000 0 0.0000 Capital shares (H shares)

4. Proposal Name: Proposal on Application for Financing and Credit Lines from Financial Institutions in 2026

Review result: Passed

Voting status: Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 303,001,612 99.6776 954,139 0.3139 25,765 0.0085

Among them: A shares 294,007,721 99.7158 812,091 0.2754 25,765 0.0088

Overseas listed foreign capital 8,993,891 98.4452 142,048 1.5548 0 0.0000 shares (H shares)

5. Proposal Name: Proposal on the 2026 Compensation Plan for the Company’s Directors Review result: Passed

Voting status:

Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 138,853,208 99.4505 726,982 0.5207 40,265 0.0288 Among them: A shares 129,717,269 99.4120 726,982 0.5571 40,265 0.0309

Outside of overseas listing 9,135,939 100.0000 0 0.0000 0 0.0000 Capital shares (H shares)

6. Proposal Name: Proposal on the Appointment of Domestic and Foreign Audit Institutions for 2026

Review result: Passed

Voting status: Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 298,636,407 98.2416 5,324,844 1.7517 20,265 0.0067

Among them: A shares 293,655,880 99.5965 1,169,432 0.3966 20,265 0.0069

Outside of overseas listing 4,980,527 54.5158 4,155,412 45.4842 0 0.0000 Capital shares (H shares)

7. Proposal title: Proposal on the formulation of the "Remuneration Management System for Directors and Senior Management Personnel" Review result: Passed

Voting status:

Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 303,203,911 99.7442 740,642 0.2436 36,963 0.0122

Among them: A shares 294,116,372 99.7526 692,242 0.2347 36,963 0.0127 Overseas listed foreign capital 9,087,539 99.4702 48,400 0.5298 0 0.0000 shares (H shares)

8. Proposal Name: Regarding the "Company's Shareholder Dividend Return Plan for the Next Three Years (2026-2028)"

motion

Review result: Passed

Voting status: Agree Disagree Abstain

Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 303,385,249 99.8038 570,767 0.1878 25,500 0.0084 Among them: A shares 294,249,310 99.7977 570,767 0.1935 25,500 0.0088

Outside of overseas listing 9,135,939 100.0000 0 0.0000 0 0.0000 Capital shares (H shares)

9. Proposal Name: Proposal on the by-election of independent non-executive directors of the fourth session of the Board of Directors of the Company

Review result: Passed Voting status:

Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 303,340,327 99.7891 628,524 0.2068 12,665 0.0042

Among them: A shares 294,252,788 99.7989 580,124 0.1967 12,665 0.0044

Overseas listed foreign capital 9,087,539 99.4702 48,400 0.5298 0 0.0000 shares (H shares)

10. Proposal Name: Proposal on the Change of Ownership Structure of Partial Fund-raising Project Sub-projects

Review result: Passed

Voting status:

Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 303,392,155 99.8061 559,498 0.1841 29,863 0.0098 Among them: A shares 294,256,216 99.8001 559,498 0.1897 29,863 0.0102

Outside of overseas listing 9,135,939 100.0000 0 0.0000 0 0.0000 Capital shares (H shares)

11. Proposal Name: Proposal on External Investment and Related Transactions

Review result: Passed

Voting status: Agree Disagree Abstain

Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 146,760,155 99.5693 597,327 0.4053 37,473 0.0254 Among them: A shares 137,624,216 99.5408 597,327 0.4320 37,473 0.0272

Outside of overseas listing 9,135,939 100.0000 0 0.0000 0 0.0000 Capital shares (H shares)

12. Proposal Name: Proposal on the Estimated Amount of External Guarantees in 2026

Review result: Passed Voting status:

Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 293,577,491 96.5774 10,387,162 3.4170 16,863 0.0055

Among them: A shares 290,831,324 98.6385 3,997,390 1.3557 16,863 0.0058

Overseas listing Foreign shares (H 2,746,167 30.0589 6,389,772 69.9411 0 0.0000

shares)

13. Proposal Name: Proposal on General Authorization for the Issuance of Domestic and Overseas Debt Financing Instruments

Review result: Passed

Voting status: Agree Disagree Abstain

Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 294,421,863 96.8552 9,533,988 3.1364 25,665 0.0084 Among them: A shares 291,428,315 98.8409 3,391,597 1.1502 25,665 0.0089

Outside of overseas listing 2,993,548 32.7667 6,142,391 67.2333 0 0.0000 Capital shares (H shares)

14. Proposal name: Proposal on the general authorization to issue additional A shares and/or H shares of the company

Review result: Passed

Voting status: Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 297,536,053 97.8797 6,412,533 2.1095 32,930 0.0108

Among them: A shares 292,975,224 99.3656 1,837,423 0.6231 32,930 0.0113

Outside of overseas listing 4,560,829 49.9218 4,575,110 50.0782 0 0.0000 Capital shares (H shares)

(2) When major matters are involved, the voting status of less than 5% of A-share shareholders should be explained.

Agree Disagree Abstain motion Bill name Proportion Proportion Proportion Serial number Number of votes Number of votes Number of votes (%) (%) (%) 3 About "2025 Profit Share 76,980,268 99.1947 596,157 0.7681 28,765 0.0372 Proposal of "Allocation Plan" 5 Regarding the directors of the company in 2026 76,837,943 99.0113 726,982 0.9367 40,265 0.0520 Compensation Plan Proposal 6 Regarding domestic appointments in 2026 76,415,493 98.4669 1,169,432 1.5068 20,265 0.0263 Proposal from the external audit institution 8 Regarding "The Company's Prospects for the Next Three Years 77,008,923 99.2316 570,767 0.7354 25,500 0.0330 (2026-2028) Shareholders Proposal on "Dividend Return Plan"

9 Regarding the by-election of the fourth session of directors of the company 77,012,401 99.2361 580,124 0.7475 12,665 0.0164 independent non-executive directors of the board of directors motion 10 Regarding some sub-projects of fundraising projects 77,015,829 99.2405 559,498 0.7209 29,863 0.0386

The project implements changes in the ownership structure of the main body more motion 11 Regarding foreign investment and related relations 76,970,390 99.1820 597,327 0.7696 37,473 0.0484 Yi's motion

12 Regarding external guarantees in 2026 73,590,937 94.8273 3,997,390 5.1509 16,863 0.0218 Estimated amount of proposals

(3) Explanation of relevant circumstances regarding voting on motions

Proposals 1-11 to be reviewed at the 2025 annual shareholders’ meeting are ordinary resolutions. Shareholders who have attended this meeting

The resolutions 12, 13 and 14 were approved by more than half of the voting rights held by shareholders (including shareholders’ agents) at the meeting; resolutions 12, 13 and 14 are special

For special resolutions, two-thirds of the voting rights held by shareholders who have attended this shareholders' meeting (including shareholders' agents)

The above review was approved. Proposals 3, 5, 6, 8, 9, 10, 11, and 12 of the 2025 Annual General Meeting of Shareholders are for A-share small and medium-sized investors.

Proposal for investors to count votes separately.

When considering Proposal No. 5 at the 2025 Annual Shareholders’ Meeting, shareholders of the company’s directors and their concerted actions

persons abstained from voting; when the 11th proposal was considered, related shareholders abstained from voting.

The shareholders' meeting also listened to the "2025 Independent Non-executive Directors' Work Report" by the company's independent non-executive directors. Report" and the 2026 annual compensation plan for the company's senior managers.

3. Lawyer’s testimony

4. The law firm witnessing this shareholder meeting: Beijing Jiayuan Law Firm

Lawyers: Wang Yuan, Chen Yun

2. Lawyer’s concluding comments:

The convening and convening procedures of the company’s shareholders’ meeting, the qualifications of the convenor and attendees and the voting procedures The voting procedures are in compliance with the provisions of the Company Law, the Rules of the Shareholders Meeting and other Chinese laws and regulations and the Articles of Association.

The result is legal and valid.

Announcement is hereby made.

Shanghai Junshi Biomedical Technology Co., Ltd.

board of directors

June 27, 2026